ReviewDiagnostics (Basel, Switzerland)2023
The Earlier You Find, the Better You Treat: Red Flags for Early Diagnosis of Inflammatory Bowel Disease.
Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Worldwide research trends in Crohn's disease treatment over the past 2 decades: a bibliometric analysis.Frontiers in pharmacology · 2024Pooled it
- Early Markers Associated with Crohn's Disease in Emergency Department Patients with New-Onset Terminal Ileitis: An Exploratory Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Multidisciplinary Management in Psoriasis: A Structured Approach for Early Comorbidity Detection and Referral.Dermatology and therapy · 2026Article
- Caution in handling switchers in pharmacoepidemiologic studies estimating treatment effects: the example of dipeptidyl peptidase-4 inhibitors and inflammatory bowel disease.American journal of epidemiology · 2026Article
- Serum phosphatidylinositol depletion associates with fecal calprotectin and disease severity in female and male IBD patients.Lipids in health and disease · 2026Article
- Possible underdiagnosis of ulcerative colitis in tertiary care can affect medication use and access to healthcare facilities.Frontiers in immunology · 2026Article
- Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naïve Patients With Early or Late Crohn's Disease: Results From the EVOLVE Expansion Study.Crohn's & colitis 360 · 2025Article
- Development and validation of a risk prediction tool for the diagnosis of inflammatory bowel disease in patients presenting in primary care with abdominal symptoms.Journal of Crohn's & colitis · 2025Article
- Patient and physician factors contributing to delays in inflammatory bowel diseases: Enhancing timely diagnosis.World journal of gastroenterology · 2025Article
- Review
- Article
- Early Identification of Pediatric Inflammatory Bowel Disease Based on a Noninvasive Multivariable Predictive Model.Journal of inflammation research · 2025Article
- Global, regional, and national burden of inflammatory bowel disease, 1990-2021: Insights from the global burden of disease 2021.International journal of colorectal disease · 2024Article
- Diagnostic delay in inflammatory bowel diseases in a German population.World journal of gastroenterology · 2024Article
- Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023.Intestinal research · 2024Article
- Evolving Landscape of Paediatric Inflammatory Bowel Disease: Insights from a Decade-Long Study in North-East Slovenia on Incidence, Management, Diagnostic Delays, and Early Biologic Intervention.Diagnostics (Basel, Switzerland) · 2024Article
- Screening and impact of comorbidities in bronchiectasis: a forward-looking perspective.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delayed diagnosis is a challenge in the management of inflammatory bowel disease (IBD). Several studies show a significant association between diagnostic delay and disease progression to complications and surgery, especially in Crohn's disease (CD). What risk factors are associated with diagnostic delay in IBD remains unclear. In order to reduce diagnostic delay, the Red Flags Index has been developed and validated. The combination of the Red Flags Index score and non-invasive biomarkers such as fecal calprotectin seems to be highly accurate in screening patients with underlying IBD to be referred for further diagnostic workup and eventual early effective treatment strategies. Our literature review aims to obtain a comprehensive overview of the impacts of diagnostic delay in IBD on the potential risk factors associated with IBD, how diagnostic tools may be effective in reducing diagnostic delay, and future perspectives in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.